Health
Survival benefit of osimertinib combination therapy in patients with T790M-positive non-small-cell lung cancer refractory to osimertinib treatment – MD Linx
MDLinx original journal summary on Lung Cancer, Oncology from Lung Cancer
Researchers assessed efficacy of osimertinib-based combination therapies in non-small cell lung cancer (NSCLC) patients harbouring
T790M mutations who developed progressive disease following treatment with osimertinib. Participants were NSCLC patients…
Continue Reading
-
Business18 hours agoWarning! These ASX 200 shares were just downgraded
-
Business11 hours agoMacquarie tips 14% upside for this ASX tech stock
-
Noosa News11 hours agoVegetables and herbs you can easily and cheaply grow from seeds
-
Business11 hours agoThis ASX 200 media stock is storming 7% higher to 52-week highs. Here’s why.